CA2904088A1 - Compositions and methods for detecting and determining a prognosis for prostate cancer - Google Patents
Compositions and methods for detecting and determining a prognosis for prostate cancer Download PDFInfo
- Publication number
- CA2904088A1 CA2904088A1 CA2904088A CA2904088A CA2904088A1 CA 2904088 A1 CA2904088 A1 CA 2904088A1 CA 2904088 A CA2904088 A CA 2904088A CA 2904088 A CA2904088 A CA 2904088A CA 2904088 A1 CA2904088 A1 CA 2904088A1
- Authority
- CA
- Canada
- Prior art keywords
- prostate cancer
- subject
- sample
- risk
- genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 160
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 159
- 238000000034 method Methods 0.000 title claims abstract description 144
- 238000004393 prognosis Methods 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 title description 3
- 238000001574 biopsy Methods 0.000 claims abstract description 23
- 230000014509 gene expression Effects 0.000 claims description 200
- 239000000523 sample Substances 0.000 claims description 173
- 108090000623 proteins and genes Proteins 0.000 claims description 125
- 210000002700 urine Anatomy 0.000 claims description 97
- 108020004999 messenger RNA Proteins 0.000 claims description 88
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 83
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 60
- 210000004369 blood Anatomy 0.000 claims description 55
- 239000008280 blood Substances 0.000 claims description 55
- 101000988394 Homo sapiens PDZ and LIM domain protein 5 Proteins 0.000 claims description 54
- 102100029181 PDZ and LIM domain protein 5 Human genes 0.000 claims description 54
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 claims description 52
- 101000883686 Homo sapiens 60 kDa heat shock protein, mitochondrial Proteins 0.000 claims description 52
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 51
- 238000004422 calculation algorithm Methods 0.000 claims description 43
- 101001076642 Homo sapiens Inosine-5'-monophosphate dehydrogenase 2 Proteins 0.000 claims description 42
- 102100025891 Inosine-5'-monophosphate dehydrogenase 2 Human genes 0.000 claims description 42
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 38
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 238000004458 analytical method Methods 0.000 claims description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 19
- 238000007477 logistic regression Methods 0.000 claims description 17
- 238000011471 prostatectomy Methods 0.000 claims description 13
- 238000011319 anticancer therapy Methods 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 12
- 238000007637 random forest analysis Methods 0.000 claims description 12
- 238000003757 reverse transcription PCR Methods 0.000 claims description 12
- 238000002405 diagnostic procedure Methods 0.000 claims description 10
- 101150090724 3 gene Proteins 0.000 claims description 9
- 238000002965 ELISA Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 238000013500 data storage Methods 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 239000013074 reference sample Substances 0.000 claims description 6
- 238000000636 Northern blotting Methods 0.000 claims description 4
- 101150029838 ERG gene Proteins 0.000 claims description 3
- 206010051482 Prostatomegaly Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 238000001794 hormone therapy Methods 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 238000002626 targeted therapy Methods 0.000 claims description 3
- 101150029129 AR gene Proteins 0.000 claims description 2
- 101150073900 PTEN gene Proteins 0.000 claims description 2
- 108091033411 PCA3 Proteins 0.000 claims 28
- 102100027314 Beta-2-microglobulin Human genes 0.000 claims 26
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims 26
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 claims 25
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 claims 25
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 22
- 101001033610 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 19
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 19
- ZUPXXZAVUHFCNV-UHFFFAOYSA-N [[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate;potassium Chemical compound [K].C1=CCC(C(=O)N)=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(=O)OCC2C(C(O)C(O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ZUPXXZAVUHFCNV-UHFFFAOYSA-N 0.000 claims 19
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 claims 17
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 claims 17
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims 16
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 15
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims 14
- 101150076800 B2M gene Proteins 0.000 claims 2
- 101150112014 Gapdh gene Proteins 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 74
- 201000011510 cancer Diseases 0.000 description 71
- 102100038358 Prostate-specific antigen Human genes 0.000 description 62
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 54
- 210000002381 plasma Anatomy 0.000 description 42
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 40
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 39
- 238000012360 testing method Methods 0.000 description 33
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 31
- 230000035945 sensitivity Effects 0.000 description 31
- -1 PCA3 Proteins 0.000 description 28
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 26
- 239000000090 biomarker Substances 0.000 description 23
- 238000003556 assay Methods 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 101710081844 Transmembrane protease serine 2 Proteins 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 238000012549 training Methods 0.000 description 12
- 238000001514 detection method Methods 0.000 description 10
- 239000011324 bead Substances 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 238000002493 microarray Methods 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000012706 support-vector machine Methods 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002962 histologic effect Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000009739 binding Methods 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 238000007475 c-index Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 2
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 2
- 238000001790 Welch's t-test Methods 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000013103 analytical ultracentrifugation Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 238000012898 one-sample t-test Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101100483843 Ustilago maydis (strain 521 / FGSC 9021) UPA1 gene Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000010801 machine learning Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 108010057248 oncogene proteins v-ets Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785375P | 2013-03-14 | 2013-03-14 | |
| US61/785,375 | 2013-03-14 | ||
| PCT/US2014/025860 WO2014160120A1 (en) | 2013-03-14 | 2014-03-13 | Compositions and methods for detecting and determining a prognosis for prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2904088A1 true CA2904088A1 (en) | 2014-10-02 |
Family
ID=51625336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2904088A Abandoned CA2904088A1 (en) | 2013-03-14 | 2014-03-13 | Compositions and methods for detecting and determining a prognosis for prostate cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140336280A1 (enExample) |
| EP (1) | EP2971177B1 (enExample) |
| JP (1) | JP6285009B2 (enExample) |
| CN (1) | CN105102636B (enExample) |
| CA (1) | CA2904088A1 (enExample) |
| WO (1) | WO2014160120A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11105808B2 (en) | 2004-11-12 | 2021-08-31 | Health Discovery Corporation | Methods for screening, predicting and monitoring prostate cancer |
| CN104561303A (zh) * | 2014-12-31 | 2015-04-29 | 南京卡迪奥密生物技术有限公司 | 人肿瘤预测性生物标志组合物及其应用 |
| WO2017103047A1 (en) * | 2015-12-17 | 2017-06-22 | Institut Curie | Use of antisense long non-coding rnas for the diagnosis of prostate cancer |
| CN106282366A (zh) * | 2016-09-09 | 2017-01-04 | 北京致成生物医学科技有限公司 | 一种与前列腺癌相关的分子标记物及其应用 |
| CN106148554A (zh) * | 2016-09-09 | 2016-11-23 | 北京致成生物医学科技有限公司 | 一种用于前列腺癌检测的标志物及其在试剂盒中的应用 |
| CN106148556A (zh) * | 2016-09-14 | 2016-11-23 | 北京致成生物医学科技有限公司 | C22orf41在前列腺癌诊断标志物中的应用 |
| CN106282382A (zh) * | 2016-09-30 | 2017-01-04 | 北京致成生物医学科技有限公司 | Loc100128842在制备诊断或预示前列腺癌产品中的用途 |
| JP2019531738A (ja) * | 2016-10-14 | 2019-11-07 | ウニヴェルズィテート チューリッヒ | 前立腺癌の診断と予後のためのインドールアミン−２，３−ジオキシゲナーゼ アッセイ |
| JP6812789B2 (ja) * | 2016-12-28 | 2021-01-13 | 富士通株式会社 | 情報処理装置、情報処理プログラム、および情報処理方法 |
| CN110760584B (zh) * | 2019-11-07 | 2022-12-09 | 深圳市华启生物科技有限公司 | 前列腺癌疾病进展生物标志物及其应用 |
| CN110760585B (zh) * | 2019-11-07 | 2022-12-09 | 深圳市华启生物科技有限公司 | 前列腺癌生物标志物及其应用 |
| US20210333280A1 (en) * | 2020-04-23 | 2021-10-28 | YatHing Biotechnology Company Limited | Methods related to the diagnosis of prostate cancer |
| US20240011996A1 (en) * | 2020-11-24 | 2024-01-11 | Korea Institute Of Science And Technology | Biomarkers for diagnosing prostate cancer, combination thereof, and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005245815B2 (en) | 2004-05-07 | 2011-06-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer |
| EP1824995A2 (en) * | 2004-11-24 | 2007-08-29 | St. George's Enterprises Limited | Diagnosis of prostate cancer |
| US8288110B2 (en) * | 2006-12-04 | 2012-10-16 | Perkinelmer Health Sciences, Inc. | Biomarkers for detecting cancer |
| EP2373816B1 (en) | 2008-12-04 | 2014-05-21 | Health Discovery Corporation | Methods for screening, predicting and monitoring prostate cancer |
| WO2010065940A1 (en) * | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| EP3524697B1 (en) * | 2009-01-07 | 2024-10-02 | Myriad Genetics, Inc. | Cancer biomarkers |
| US20120041274A1 (en) * | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| US20130058925A1 (en) * | 2010-02-26 | 2013-03-07 | Board Of Regents, The University Of Texas System | Epithelial biomarkers for cancer prognosis |
| AU2011352167A1 (en) | 2010-12-28 | 2013-07-11 | Caris Mpi, Inc. | Molecular profiling for cancer |
| WO2012092490A1 (en) * | 2010-12-30 | 2012-07-05 | Quest Diagnostics Investments Incorporated | Diagnosis of prostate cancer |
| CA2827894A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| US20140066325A1 (en) * | 2011-03-17 | 2014-03-06 | The Brigham And Women's Hospital, Inc. | Protein Biomarkers for the Diagnosis of Prostate Cancer |
| WO2012135008A1 (en) * | 2011-03-26 | 2012-10-04 | Oregon Health And Science University | Gene expression predictors of cancer prognosis |
| CN102912030B (zh) * | 2012-11-08 | 2014-07-30 | 端鹏 | 用于前列腺癌早期诊断的引物对、探针和试剂盒 |
-
2014
- 2014-03-13 WO PCT/US2014/025860 patent/WO2014160120A1/en not_active Ceased
- 2014-03-13 CA CA2904088A patent/CA2904088A1/en not_active Abandoned
- 2014-03-13 US US14/208,850 patent/US20140336280A1/en not_active Abandoned
- 2014-03-13 EP EP14775449.3A patent/EP2971177B1/en active Active
- 2014-03-13 JP JP2016501985A patent/JP6285009B2/ja not_active Expired - Fee Related
- 2014-03-13 CN CN201480015039.9A patent/CN105102636B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN105102636A (zh) | 2015-11-25 |
| EP2971177A1 (en) | 2016-01-20 |
| WO2014160120A1 (en) | 2014-10-02 |
| EP2971177B1 (en) | 2019-09-11 |
| EP2971177A4 (en) | 2016-11-09 |
| CN105102636B (zh) | 2019-08-13 |
| HK1213297A1 (zh) | 2016-06-30 |
| JP2016514966A (ja) | 2016-05-26 |
| US20140336280A1 (en) | 2014-11-13 |
| JP6285009B2 (ja) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2971177B1 (en) | Compositions and methods for detecting and determining a prognosis for prostate cancer | |
| EP2619321B1 (en) | Biomarkers for differentiating melanoma from benign nevus in the skin | |
| JP6049739B2 (ja) | 前立腺癌の分類のためのマーカー遺伝子 | |
| Agell et al. | A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression | |
| JP2016505247A5 (enExample) | ||
| WO2012158780A2 (en) | Lung cancer signature | |
| JP2012526550A (ja) | 胃ガンの検出用マーカー | |
| EP2895865A1 (en) | Bladder cancer detection composition kit, and associated methods | |
| JP2011525106A (ja) | 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法 | |
| WO2012125411A1 (en) | Methods of predicting prognosis in cancer | |
| US20150344962A1 (en) | Methods for evaluating breast cancer prognosis | |
| US10233502B2 (en) | Compositions for and methods of detecting, diagnosing, and prognosing thymic cancer | |
| KR101182974B1 (ko) | 림프종 진단 또는 예후 마커로서 Ｐｅｌｌｉｎｏ 1 | |
| CN110573629B (zh) | 用于诊断早期胰腺癌的方法和试剂盒 | |
| US20040241707A1 (en) | Enhanced diagnostic potential of prostate-specific antigen expressing cells | |
| JP6977965B2 (ja) | 卵巣癌組織型鑑別方法 | |
| EP2457096A2 (en) | Phenotyping tumor-infiltrating leukocytes | |
| JP2020072705A (ja) | 膀胱癌を検出するための尿マーカー | |
| JPWO2015137406A1 (ja) | 肺扁平上皮癌と肺腺癌の鑑別評価方法 | |
| WO2019134994A1 (en) | Prognostic biomarkers for human papillomavirus positive cancers | |
| RU2817940C1 (ru) | Способ прогнозирования риска летального исхода в первые 4 года от начала противоопухолевого лечения у больных плоскоклеточным раком легкого | |
| HK1213297B (zh) | 用於檢測和測定前列腺癌預後的組合物和方法 | |
| JP2021093955A (ja) | 膵管内乳頭状粘液性腫瘍由来膵癌または膵癌を検出する方法およびキット | |
| WO2012010661A1 (en) | Methods for determining a prognosis for survival for a patient with leukaemia | |
| JPWO2015115545A1 (ja) | 乳がんの転移又は再発リスクの評価方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190116 |
|
| FZDE | Discontinued |
Effective date: 20210831 |